SRR1313130
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- UV_RESPONSE_DN+0.350
- ANGIOGENESIS+0.320
- ESTROGEN_RESPONSE_EARLY+0.310
- WNT_BETA_CATENIN_SIGNALING+0.300
- HEDGEHOG_SIGNALING+0.230
- ALLOGRAFT_REJECTION+0.220
- MYOGENESIS+0.210
- TNFA_SIGNALING_VIA_NFKB+0.210
- APICAL_SURFACE+0.190
- KRAS_SIGNALING_UP+0.190
Top 10 suppressed
- E2F_TARGETS-0.650
- G2M_CHECKPOINT-0.630
- MYC_TARGETS_V2-0.550
- MTORC1_SIGNALING-0.460
- MITOTIC_SPINDLE-0.420
- MYC_TARGETS_V1-0.380
- DNA_REPAIR-0.350
- GLYCOLYSIS-0.310
- UNFOLDED_PROTEIN_RESPONSE-0.290
- OXIDATIVE_PHOSPHORYLATION-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1313091 | — | A | 0.898 |
| 2 | TCGA-BH-A0DP-01A-21R-A056-07 | — | A | 0.889 |
| 3 | SRR1313129 | — | A | 0.883 |
| 4 | TCGA-A2-A0EW-01A-21R-A115-07 | — | A | 0.879 |
| 5 | TCGA-CR-7393-01A-11R-2016-07 | — | — | 0.876 |
| 6 | TCGA-D8-A27I-01A-11R-A16F-07 | — | A | 0.872 |
| 7 | TCGA-75-6203-01A-11R-1755-07 | — | cohortA1 | 0.872 |
| 8 | TCGA-A2-A0ES-01A-11R-A115-07 | — | A | 0.872 |
| 9 | SRR35579845 | — | A | 0.868 |
| 10 | TCGA-A7-A5ZW-01A-12R-A29R-07 | — | A | 0.858 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 30 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| UV_RESPONSE_DN | 0.350 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.320 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.310 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.300 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.220 | Idelalisib | — uncovered |
| MYOGENESIS | 0.210 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.210 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| APICAL_JUNCTION | 0.170 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.170 | Inavolisib | — uncovered |
| APOPTOSIS | 0.150 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.150 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.150 | Idelalisib | — uncovered |
| BILE_ACID_METABOLISM | 0.140 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.140 | Temsirolimus | — uncovered |
| INFLAMMATORY_RESPONSE | 0.130 | Idelalisib | — uncovered |